For citations:
Korotaeva T.V., Zotkin E.G., Nesmeyanova O.B., Vezikova N.N., Ershova O.B., Izmozzherova N.V., Petrova M.S., Kastanyan A.A., Yakupova S.P., Agafina A.S., Stanislav M.L., Novoderezhkina E.A., Nasonov E.L., Mease P.J. Use of the interleukin-17A inhibitor secukinumab in psoriatic arthritis: a subanalysis of the Russian population in the international randomized clinical trials FUTURE 1 and FUTURE 2. Rheumatology Science and Practice. 2017;55(2):151-158. (In Russ.) https://doi.org/10.14412/1995-4484-2017-151-158
Email this article 